Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
出版年份 2018 全文链接
标题
Osimertinib in Japanese patients with EGFR
T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
作者
关键词
-
出版物
CANCER SCIENCE
Volume 109, Issue 6, Pages 1930-1938
出版商
Wiley
发表日期
2018-04-26
DOI
10.1111/cas.13623
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer
- (2016) Ferdinandos Skoulidis et al. CLINICAL CANCER RESEARCH
- The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
- (2016) Daniel S.W. Tan et al. Journal of Thoracic Oncology
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
- (2016) Glenwood Goss et al. LANCET ONCOLOGY
- Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
- (2016) Kenzo Soejima et al. Expert Review of Clinical Pharmacology
- EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
- (2015) Kyoko Otsuka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
- (2015) E. Miyauchi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
- (2013) Nobuyuki Katakami et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma
- (2011) Hidetaka Uramoto et al. LUNG CANCER
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
- (2010) M. L. Sos et al. CANCER RESEARCH
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
- (2010) Geoffrey R. Oxnard et al. CLINICAL CANCER RESEARCH
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation